Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study.

Song Y, Azari FS, Metzger DA, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2019 Sep 4. doi: 10.1245/s10434-019-07783-0. [Epub ahead of print]

PMID:
31485823
2.

Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.

Jain V, Venigalla S, Sebro RA, Karakousis GC, Wilson RJ 2nd, Weber KL, Shabason JE.

Cancer Med. 2019 Sep 4. doi: 10.1002/cam4.2441. [Epub ahead of print]

3.

Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.

Kwak M, Song Y, Gimotty PA, Farrow NE, Tieniber AD, Davick JG, Tortorello GN, Beasley GM, Slingluff CL Jr, Karakousis GC.

Ann Surg Oncol. 2019 Aug 7. doi: 10.1245/s10434-019-07694-0. [Epub ahead of print]

PMID:
31392529
4.

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.

Song Y, Tieniber AD, Gimotty PA, Mitchell TC, Amaravadi RK, Schuchter LM, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2019 Jul 3. doi: 10.1245/s10434-019-07599-y. [Epub ahead of print]

PMID:
31270717
5.

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies.

Song Y, Bruce AN, Fraker DL, Karakousis GC.

J Surg Oncol. 2019 Sep;120(3):540-549. doi: 10.1002/jso.25600. Epub 2019 Jul 2.

PMID:
31267571
6.

Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL.

Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25.

PMID:
31239316
7.

National trends in centralization and perioperative outcomes of complex operations for cancer.

Song Y, Tieniber AD, Roses RE, Fraker DL, Kelz RR, Karakousis GC.

Surgery. 2019 Jun 20. pii: S0039-6060(19)30182-5. doi: 10.1016/j.surg.2019.03.025. [Epub ahead of print]

PMID:
31230839
8.

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.

Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ.

Nature. 2019 Jul;571(7764):211-218. doi: 10.1038/s41586-019-1325-x. Epub 2019 Jun 17.

PMID:
31207603
9.

Trends in practice patterns and outcomes: A decade of sarcoma care in the United States.

Song Y, Ecker BL, Tang R, Maggino L, Roses RE, DeMatteo RP, Fraker DL, Karakousis GC.

Surg Oncol. 2019 Jun;29:168-177. doi: 10.1016/j.suronc.2019.05.018. Epub 2019 May 21.

PMID:
31196484
10.

Predictors and outcomes of jejunostomy tube placement at the time of pancreatoduodenectomy.

Song Y, Tieniber AD, Vollmer CM, Lee MK, Roses RE, Fraker DL, Kelz RR, Karakousis GC.

Surgery. 2019 Jun;165(6):1136-1143. doi: 10.1016/j.surg.2019.03.007. Epub 2019 May 7.

PMID:
31076092
11.

Let's Not Forget About Regional Therapy for the Treatment of Locally Advanced Extremity Melanoma.

Karakousis GC.

Ann Surg Oncol. 2019 Aug;26(8):2322-2324. doi: 10.1245/s10434-019-07430-8. Epub 2019 May 6. No abstract available.

PMID:
31062208
12.

Multispectral photoacoustic imaging for the detection of subclinical melanoma.

Sinnamon AJ, Neuwirth MG, Song Y, Schultz SM, Liu S, Xu X, Sehgal CM, Karakousis GC.

J Surg Oncol. 2019 Jun;119(8):1070-1076. doi: 10.1002/jso.25447. Epub 2019 Mar 15.

PMID:
30874312
13.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.

Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25.

14.

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.

Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK.

Cancer Discov. 2019 Mar;9(3):396-415. doi: 10.1158/2159-8290.CD-18-0348. Epub 2018 Dec 18. Erratum in: Cancer Discov. 2019 Jul;9(7):981.

PMID:
30563872
15.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2019 Jan;565(7738):E4. doi: 10.1038/s41586-018-0814-7.

PMID:
30532003
16.

Melanoma of unknown primary.

Song Y, Karakousis GC.

J Surg Oncol. 2019 Jan;119(2):232-241. doi: 10.1002/jso.25302. Epub 2018 Nov 27. Review.

PMID:
30481368
17.

Microsatellitosis in Patients with Melanoma.

Karakousis GC, Gimotty PA, Leong SP, Pockaj BA, White RL, O'Donoghue C, Sinnamon AJ, Bartlett EK, Dueck AC, Gould Rothberg BE, Messina JL, Vetto JT, Sondak VK, Schneebaum S, Kashani-Sabet M, Han D, Faries MB, Zager JS; with the Sentinel Lymph Node Working Group.

Ann Surg Oncol. 2019 Jan;26(1):33-41. doi: 10.1245/s10434-018-7006-4. Epub 2018 Nov 12.

PMID:
30421045
18.

Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis.

Ecker BL, Kaur A, Douglass SM, Webster MR, Almeida FV, Marino GE, Sinnamon AJ, Neuwirth MG, Alicea GM, Ndoye A, Fane M, Xu X, Sim MS, Deutsch GB, Faries MB, Karakousis GC, Weeraratna AT.

Cancer Discov. 2019 Jan;9(1):82-95. doi: 10.1158/2159-8290.CD-18-0168. Epub 2018 Oct 2.

PMID:
30279172
19.

Response to Comment on "Does Surgeon Sex Matter? Practice Patterns and Outcomes of Female and Male Surgeons".

Sharoky CE, Karakousis GC, Kelz RR.

Ann Surg. 2019 Aug;270(2):e25. doi: 10.1097/SLA.0000000000003047. No abstract available.

PMID:
30216217
20.

Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): A National Cancer Database study.

Hanna AN, Sinnamon AJ, Roses RE, Kelz RR, Elder DE, Xu X, Pockaj BA, Zager JS, Fraker DL, Karakousis GC.

J Am Acad Dermatol. 2019 Feb;80(2):433-440. doi: 10.1016/j.jaad.2018.08.022. Epub 2018 Aug 27.

PMID:
30165160
21.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W.

Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.

22.

Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma.

Sinnamon AJ, Song Y, Sharon CE, Yang YX, Elder DE, Zhang PJ, Xu X, Roses RE, Kelz RR, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2018 Nov;25(12):3469-3475. doi: 10.1245/s10434-018-6647-7. Epub 2018 Jul 24.

PMID:
30043316
23.

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma-Reply.

Sinnamon AJ, Gimotty PA, Karakousis GC.

JAMA Oncol. 2018 Aug 1;4(8):1136-1137. doi: 10.1001/jamaoncol.2018.0898. No abstract available.

PMID:
29902301
24.

Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma.

Sharon CE, Sinnamon AJ, Ming ME, Chu EY, Fraker DL, Karakousis GC.

JAMA Dermatol. 2018 May 1;154(5):574-580. doi: 10.1001/jamadermatol.2018.0233.

25.

Disparities in resection of hepatic metastases in colon cancer.

Neuwirth MG, Epstein AJ, Karakousis GC, Mamtani R, Paulson EC.

J Gastrointest Oncol. 2018 Feb;9(1):126-134. doi: 10.21037/jgo.2017.11.03.

26.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21.

PMID:
29563139
27.

The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.

Sinnamon AJ, Sharon CE, Song Y, Neuwirth MG, Elder DE, Xu X, Chu EY, Ming ME, Fraker DL, Gimotty PA, Karakousis GC.

J Am Acad Dermatol. 2018 Aug;79(2):245-251. doi: 10.1016/j.jaad.2018.02.066. Epub 2018 Mar 5.

PMID:
29518458
28.

Transected thin melanoma: Implications for sentinel lymph node staging.

Herbert G, Karakousis GC, Bartlett EK, Zaheer S, Graham D, Czerniecki BJ, Fraker DL, Ariyan C, Coit DG, Brady MS.

J Surg Oncol. 2018 Mar;117(4):567-571. doi: 10.1002/jso.24930. Epub 2017 Nov 30.

29.

Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.

Newton AD, Predina JD, Xia L, Roses RE, Karakousis GC, Dempsey DT, Williams NN, Kucharczuk JC, Singhal S.

Ann Surg Oncol. 2018 Jan;25(1):318-325. doi: 10.1245/s10434-017-6238-z. Epub 2017 Nov 16.

PMID:
29147928
30.

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Sinnamon AJ, Neuwirth MG, Gimotty PA, Gangadhar TC, Amaravadi RK, Schuchter LM, Karakousis GC.

JAMA Oncol. 2018 Jan 1;4(1):126-128. doi: 10.1001/jamaoncol.2017.3462. No abstract available.

31.

Prophylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative Morbidity.

Sinnamon AJ, Neuwirth MG, Vining CC, Sharoky CE, Yang YX, Kelz RR, Fraker DL, Roses RE, Karakousis GC.

Ann Surg Oncol. 2018 Jan;25(1):239-245. doi: 10.1245/s10434-017-6093-y. Epub 2017 Oct 24.

PMID:
29067602
32.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

33.

Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis.

Neuwirth MG, Song Y, Sinnamon AJ, Fraker DL, Zager JS, Karakousis GC.

Ann Surg Oncol. 2017 Dec;24(13):3803-3810. doi: 10.1245/s10434-017-6109-7. Epub 2017 Oct 11. Review.

PMID:
29022281
34.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27. Erratum in: Nature. 2019 Jan;565(7738):E4.

35.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz JD, Ertl HCJ.

Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

36.

Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?

Neuwirth MG, Bierema C, Sinnamon AJ, Fraker DL, Kelz RR, Roses RE, Karakousis GC.

Cancer. 2018 Jan 1;124(1):125-135. doi: 10.1002/cncr.30977. Epub 2017 Sep 7.

37.

Understanding readmissions following operations of the thyroid and parathyroid glands.

Collier K, Sataloff J, Wirtalla C, Kuo L, Karakousis GC, Kelz RR.

Am J Surg. 2017 Sep;214(3):501-508. doi: 10.1016/j.amjsurg.2017.01.008. Epub 2017 Jan 10.

PMID:
28818283
38.

Hospitalization in the Year Preceding Major Oncologic Surgery Increases Risk for Adverse Postoperative Events.

Sharoky CE, Collier KT, Wirtalla CJ, Sinnamon AJ, Neuwirth MG, Kuo LE, Roses RE, Fraker DL, Karakousis GC, Kelz RR.

Ann Surg Oncol. 2017 Nov;24(12):3477-3485. doi: 10.1245/s10434-017-6032-y. Epub 2017 Aug 14.

PMID:
28808930
39.

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.

Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan JB, Xu X, Amaravadi RK, Schuchter LM, Karakousis GC, Hwang WT, Carpenter EL.

Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81. doi: 10.1111/pcmr.12623. Epub 2017 Oct 23.

40.

Does Surgeon Sex Matter?: Practice Patterns and Outcomes of Female and Male Surgeons.

Sharoky CE, Sellers MM, Keele LJ, Wirtalla CJ, Karakousis GC, Morris JB, Kelz RR.

Ann Surg. 2018 Jun;267(6):1069-1076. doi: 10.1097/SLA.0000000000002460.

PMID:
28742695
41.

Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Sinnamon AJ, Neuwirth MG, Yalamanchi P, Gimotty P, Elder DE, Xu X, Kelz RR, Roses RE, Chu EY, Ming ME, Fraker DL, Karakousis GC.

JAMA Dermatol. 2017 Sep 1;153(9):866-873. doi: 10.1001/jamadermatol.2017.2497.

42.

Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma.

Sinnamon AJ, Neuwirth MG, Bartlett EK, Zaheer S, Etherington MS, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

J Surg Oncol. 2017 Dec;116(7):848-855. doi: 10.1002/jso.24743. Epub 2017 Jun 26.

PMID:
28650537
43.

Adjuvant chemotherapy in resectable synovial sarcoma.

Vining CC, Sinnamon AJ, Ecker BL, Kelz RR, Fraker DL, Roses RE, Karakousis GC.

J Surg Oncol. 2017 Sep;116(4):550-558. doi: 10.1002/jso.24688. Epub 2017 Jun 5.

PMID:
28580620
44.

Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature.

Datta J, Ecker BL, Neuwirth MG, Geha RC, Fraker DL, Roses RE, Karakousis GC.

Surg Oncol. 2017 Jun;26(2):117-124. doi: 10.1016/j.suronc.2017.01.008. Epub 2017 Feb 2. Review.

PMID:
28577717
45.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ.

Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.

46.

Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.

Ecker BL, McMillan MT, Datta J, Lee MK, Karakousis GC, Vollmer CM Jr, Drebin JA, Fraker DL, Roses RE.

Cancer. 2017 May 15;123(6):967-976. doi: 10.1002/cncr.30439. Epub 2016 Nov 7.

47.

Lymph node dissection for melanoma: where do we stand?

Neuwirth MG, Bartlett EK, Karakousis GC.

Melanoma Manag. 2017 Mar;4(1):49-59. doi: 10.2217/mmt-2016-0023. Epub 2017 Mar 3. Review.

48.

Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: A matched cohort study.

Ecker BL, McMillan MT, Datta J, Dempsey DT, Karakousis GC, Fraker DL, Drebin JA, Mamtani R, Giantonio BJ, Roses RE.

Eur J Cancer. 2016 Dec;69:135-141. doi: 10.1016/j.ejca.2016.09.027. Epub 2016 Nov 4.

PMID:
27821316
49.

Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.

Ecker BL, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Kelz RR, Roses RE, Drebin JA, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2017 Feb;24(2):425-433. doi: 10.1245/s10434-016-5641-1. Epub 2016 Oct 26.

PMID:
27785659
50.

Obesity is not associated with increased morbidity in patients undergoing cytoreductive surgery with intraperitoneal chemotherapy.

Neuwirth MG, Bartlett EK, Roses RE, Fraker DL, Kelz RR, Karakousis GC.

J Surg Oncol. 2016 Oct;114(5):619-624. doi: 10.1002/jso.24366. Epub 2016 Jul 7.

PMID:
27383501

Supplemental Content

Loading ...
Support Center